SynthesisKidney3602026
Effect of Preprocedural Desmopressin on Complications after Kidney Biopsy: A Systematic Review and Meta-Analysis.
Synthesis in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
key pointsPreprocedural Desmopressin reduced the rate of bleeding complications when given intranasally or subcutaneously but not intravenously. Desmopressin results in greater odds of hyponatremia, and thus requires monitoring.
backgroundDesmopressin has a theoretical rationale to reduce procedural bleeding risk, but the results from randomized controlled trials are mixed.
methodsPubMed, Embase, and Google Scholar were searched on October 27, 2025, to identify studies evaluating Desmopressin administered before kidney biopsy. Risk of bias was assessed using the Cochrane risk of bias 2.0 tool. Statistical analysis was performed using RevMan software to calculate odds ratios (ORs) and assess heterogeneity with the I 2 statistic. Publication bias was assessed with the Egger's test. A sensitivity analysis was performed due to heterogeneity via the leave-one-out method with revised estimated odds presented thereafter.
resultsSeventeen studies including 5394 participants were analyzed. The pooled estimated OR for total bleeding was 0.89 (0.59 to 1.36), P = 0.60, I 2 =85%. In subgroup analysis, the pooled estimated OR for subcutaneous administration was 0.37 (0.21 to 0.65), P < 0.001, I 2 =0%; intravenous administration was 1.47 (1.05 to 2.05), P = 0.03, I 2 =61%; intranasal administration was 0.68 (0.30 to 1.56), P = 0.37, I 2 =87%; and eGFR <60 ml/min per 1.73 m 2 was 0.74 (0.40 to 1.37) P = 0.34, I 2 =81%. After sensitivity analysis, the revised OR for intranasal administration was 0.42 (0.31 to 0.59), P < 0.001 and for eGFR <60 was 0.55 (0.38 to 0.81), P = 0.002. The pooled estimated OR for severe hyponatremia was 3.85 (95% confidence interval, 2.12 to 7.00; P < 0.001; I 2 =33%).
conclusionsOverall, there was no reduction in odds of bleeding but with high between-group heterogeneity. There were lower odds of bleeding in the intranasal and subcutaneous administration subgroups. Desmopressin resulted in higher odds of hyponatremia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.